(Q44253853)

1 December 2017

title

Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006. (English)

1 reference

1 December 2017

1 reference

Howard G Birnbaum

1

1 reference

1 December 2017

Crystal Pike

2

1 reference

1 December 2017

Ritesh Banerjee

3

1 reference

1 December 2017

Tracy Waldman

4

1 reference

1 December 2017

Mary Cifaldi

5

1 reference

1 December 2017

publication date

1 April 2012

1 reference

1 December 2017

1 reference

1 December 2017

volume

30

1 reference

1 December 2017

issue

4

1 reference

1 December 2017

page(s)

323-336

1 reference

https://scigraph.springernature.com/pub.10.2165/11589470-000000000-00000

1 December 2017

exact match

0 references

cites work

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

Direct and indirect costs of rheumatoid arthritis to an employer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

Management of patients in fast track surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

The evolving role of statins in the management of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

Substantial gains in bias reduction from matching with a variable number of controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

Sex differences in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

Sex differences in rheumatoid arthritis: more than meets the eye..

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

Early experience with pay-for-performance: from concept to practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589470-000000000-00000

Comorbidities in rheumatoid arthritis

21 January 2018

1 reference

12 December 2020

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

12 December 2020

Software for optimal matching in observational studies.

1 reference

12 December 2020

Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls.

1 reference

12 December 2020

Which medical conditions account for the rise in health care spending?

1 reference

12 December 2020

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

1 reference

12 December 2020

Work disability in early rheumatoid arthritis

1 reference

12 December 2020

Links between radiological change, disability, and pathology in rheumatoid arthritis

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

Differences by sex in correlates of work status in rheumatoid arthritis patients

1 reference

12 December 2020

Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study

1 reference

12 December 2020

Household income and earnings losses among 6,396 persons with rheumatoid arthritis.

1 reference

12 December 2020

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

1 reference

12 December 2020

Impact of specialty drugs on the use of other medical services.

1 reference

12 December 2020

Early statin treatment following acute myocardial infarction and 1-year survival

1 reference

12 December 2020

Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction

1 reference

12 December 2020

Hospital consolidation and costs: another look at the evidence

1 reference

12 December 2020

10.2165/11589470-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

1 December 2017

1029118513

0 references

1 reference